scholarly journals N-Acetylcysteine Combined With Dexamethasone Treatment Improves Sudden Sensorineural Hearing Loss and Attenuates Hair Cell Death Caused by ROS Stress

2021 ◽  
Vol 9 ◽  
Author(s):  
Xue Bai ◽  
Sen Chen ◽  
Kai Xu ◽  
Yuan Jin ◽  
Xun Niu ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Hair Cells ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Control Group ◽  
Hearing Recovery ◽  
Potential Strategy ◽  
Intratympanic Dexamethasone ◽  
Pure Tone Threshold

Sudden sensorineural hearing loss (SSNHL) is a common emergency in the world. Increasing evidence of imbalance of oxidant–antioxidant were found in SSNHL patients. Steroids combined with antioxidants may be a potential strategy for the treatment of SSNHL. In cochlear explant experiment, we found that N-acetylcysteine (NAC) combined with dexamethasone can effectively protect hair cells from oxidative stress when they were both at ineffective concentrations alone. A clinic trial was designed to explore whether oral NAC combined with intratympanic dexamethasone (ITD) as a salvage treatment has a better therapeutic effect. 41 patients with SSNHL were randomized to two groups. 23 patients in control group received ITD therapy alone, while 18 patient s in NAC group were treated with oral NAC and ITD. The patients were followed-up on day 1st (initiation of treatment) and day 14th. Overall, there was no statistical difference in final pure-tone threshold average (PTA) improvement between those two groups. However, a significant hearing gain at 8,000 Hz was observed in NAC group. Moreover, the hearing recovery rates of NAC group is much higher than that in control group. These results demonstrated that oral NAC in combination with ITD therapy is a more effective therapy for SSNHL than ITD alone.

Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss

2005 ◽  
Vol 132 (6) ◽  
pp. 902-905 ◽  
Author(s):  
Robert A. Battista
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Treatment Protocol ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Additional Patient ◽  
Prospective Clinical Study ◽  
Partial Recovery ◽  
Hearing Recovery ◽  
Intratympanic Dexamethasone

OBJECTIVES: To determine hearing recovery by using intratympanic dexamethasone for profound, idiopathic sudden sensorineural hearing loss (ISSNHL). STUDY DESIGN AND SETTING: A prospective, clinical study was performed of 25 consecutive patients seen with profound ISSNHL. Patients received 4 intratympanic treatments of dexamethasone over the course of 2 weeks. Complete hearing recovery was defined as the final pure-tone average (PTA) within 10 dB of baseline. Partial recovery was defined as a final PTA with >50% hearing. The hearing in the contralateral ear was used as baseline. RESULTS: The average time to treatment was 28 days. Two patients had significant hearing recovery, and 1 additional patient had partial recovery. The 2 patients with significant hearing recovery were treated within 9 days of onset of hearing loss. CONCLUSIONS: By using the treatment protocol and definition of hearing recovery of this study, intratympanic dexamethasone does not result in significant hearing improvement for patients with profound ISSNHL. There is a possible trend for improved hearing results if intratympanic treatment is performed within 11 days of onset of hearing loss.

scholarly journals Thyroid-Related Hormone Levels in Clinical Patients With Moderately Severe-to-Profound Sudden Sensorineural Hearing Loss: A Prospective Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhong Zheng ◽  
Ying Shen ◽  
Liang Xia ◽  
Lili Xiao ◽  
Yuanyuan Sun ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Venous Blood ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Favorable Outcome ◽  
Control Group ◽  
Hormone Levels ◽  
Hearing Recovery ◽  
Tsh Levels

Objectives: Sudden sensorineural hearing loss (SSNHL) is a common otological emergency, causing a measure of hearing loss and affecting the quality of life. This study aims to investigate the association of thyroid-related hormone levels with moderately severe-to-profound SSNHL.Methods: The study included 70 patients with moderately severe-to-profound SSNHL and 100 age- and sex-matched healthy controls. Peripheral venous blood samples were taken from the participants, and their thyroid-related hormone levels were measured at admission and 1 week after treatment.Results: In moderately severe-to-profound SSNaHL patients, the concentrations of total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), and thyroid-stimulating hormone (TSH) (all P < 0.05) were significantly lower than in the control group. The TT3, TT4, FT3, and TSH levels were significantly higher in the effective group than in the ineffective group (all P < 0.05). Linear correlation analysis revealed that TSH level (R = 0.707, P < 0.05) elevation after treatment successfully predicted a favorable outcome of hearing recovery. Logistic regression analyses suggested low FT3 and TSH levels to be independent occurrence predictors, while the increase of TSH level may be an independent favorable outcome predictor.Conclusions: The results suggest that low FT3 and TSH levels are risk factors for moderately severe-to-profound SSNHL. By discovering the positive association between TSH elevation and hearing recovery, along with the potential novel predictors of FT3 and TSH, our study may contribute valuable insights to the research and treatment of moderately severe-to-profound SSNHL.

scholarly journals Thyroid-related Hormone Levels in Clinical Patients with Moderately Severe-to-Profound Sudden Sensorineural Hearing Loss: A Prospective Study

2021 ◽  
Author(s):  
Zhong Zheng ◽  
Ying Shen ◽  
Liang Xia ◽  
Lili Xiao ◽  
Yuanyuan Sun ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Characteristic Curve ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Favorable Outcome ◽  
Control Group ◽  
Hormone Levels ◽  
Hearing Recovery ◽  
Tsh Levels

Abstract Background and PurposeSSNHL is a common otology emergency, that may lead to hearing loss and impact quality of life. This study aims to investigate the association of thyroid-related hormone levels with moderately severe-to-profound sudden sensorineural hearing loss (SSNHL) that may contribute to treatment optimization.MethodsThe study included 70 patients with moderately severe-to-profound SSNHL and 100 age- and sex-matched healthy controls. Peripheral venous blood samples were taken from the participants, and their thyroid-related hormone levels were measured at admission and one week after treatment.ResultsThyroid-related hormone levels of total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), and thyroid stimulating hormone (TSH) (all P < 0.05) were found to be at significantly lower levels in moderately severe-to-profound SSNHL patients to that of the control group. The increases of TT3, TT4, FT3, and TSH levels were significantly higher in the effective group than that in the ineffective group (all P < 0.05). Through receiver operating characteristic curve analyses, areas under the curve were 0.737, 0.636, 0.837, 0.458, and 0.903 for TT3, TT4, FT3, FT4, and TSH, respectively. Linear correlation analysis revealed that TSH level (R = 0.707, P < 0.05) elevation after treatment successfully predicted a favorable outcome of hearing recovery. Logistic regression analyses suggest low FT3 and TSH levels to be independent occurrence predictors while the increase of TSH level may be an independent favorable outcome predictor.ConclusionsThe results suggest low FT3 and TSH levels are risk factors for moderately severe-to-profound SSNHL. By discovering the positive association between TSH elevation and hearing recovery, along with the potential novel predictors of FT3 and TSH, our study may contribute valuable insights to the study and treatment of moderately severe-to-profound SSNHL.Trial RegistrationChinese Clinical Trial Registry; ChiCTR1800017072. Registered 10 July 2017, http://www.chictr.org.cn/showproj.aspx?proj=29023

Simultaneous versus Subsequent Intratympanic Dexamethasone for Idiopathic Sudden Sensorineural Hearing Loss

2011 ◽  
Vol 145 (6) ◽  
pp. 1016-1021 ◽  
Author(s):  
Moo Kyun Park ◽  
Chi Kyou Lee ◽  
Kye Hoon Park ◽  
Jong Dae Lee ◽  
Chan Goo Lee ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Dexamethasone Treatment ◽  
Early Recovery ◽  
Dexamethasone Group ◽  
Number Of Patients ◽  
Hearing Recovery ◽  
Intratympanic Dexamethasone

Objective. The authors compared the efficacy of simultaneous and subsequent intratympanic dexamethasone injections for the treatment of idiopathic sudden sensorineural hearing loss. Study Design. Prospective randomized controlled multicenter study. Setting. Three tertiary university hospitals. Subjects and Methods. In the simultaneous intratympanic dexamethasone group, intratympanic dexamethasone was given initially with systemic steroids. In the subsequent intratympanic dexamethasone group, intratympanic dexamethasone was given 7 days after systemic treatment. The authors compared hearing outcomes between the groups according to Siegel’s criteria and frequency (0.25, 0.5, 1, 2, 3, 4, 6, and 8 kHz). Results. A total of 88 patients were analyzed in this study. There was no difference between the groups in hearing recovery according to Siegel’s criteria or frequencies. Neither recovery time nor early recovery differed between the groups. In the subsequent intratympanic dexamethasone group, 15 patients showed hearing recovery within 7 days and did not need intratympanic dexamethasone treatment. After intratympanic dexamethasone treatment, >28% (25/88) of the patients complained of otalgia, transient dizziness, ear fullness, and headache. Five percent of the patients showed small, transient perforations and otorrhea during intratympanic dexamethasone treatment. Conclusions. Simultaneous intratympanic dexamethasone did not confer an additional hearing gain or earlier recovery rate compared with subsequent intratympanic dexamethasone. A considerable number of patients did not need intratympanic dexamethasone for idiopathic sudden sensorineural hearing loss, and some patients experienced unnecessary side effects due to intratympanic dexamethasone. Therefore, the use of intratympanic dexamethasone is recommended only for subsequent or salvage treatment of idiopathic sudden sensorineural hearing loss after systemic steroid treatment.

Plasma levels of endothelial cell-specific molecule-1 and pentraxin-3 in idiopathic sudden sensorineural hearing loss

2018 ◽  
Vol 132 (11) ◽  
pp. 995-999 ◽  
Author(s):  
F Gündoğan ◽  
A Bayram ◽  
M Kalkan ◽  
İ Özcan
Keyword(s):  
Hearing Loss ◽  
Endothelial Cell ◽  
Sensorineural Hearing Loss ◽  
Group Treatment ◽  
Plasma Levels ◽  
Pure Tone Audiometry ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Control Group ◽  
Pentraxin 3

AbstractObjectivesTo evaluate the plasma levels of endothelial cell-specific molecule-1 (ESM-1) and pentraxin-3 (PTX-3) in patients with idiopathic sudden sensorineural hearing loss, and to compare the pre- and post-treatment levels in patients responsive and non-responsive to therapy.MethodsThe study included 108 subjects: 51 with idiopathic sudden sensorineural hearing loss and 57 controls. For ESM-1 and PTX-3 analyses, blood samples were collected before and three months after treatment initiation in the idiopathic sudden sensorineural hearing loss group and once for the control group. Treatment response was evaluated three months after therapy initiation with pure tone audiometry, and the patients were divided into two groups: responsive and non-responsive to treatment.ResultsSerum ESM-1 levels were significantly higher in the idiopathic sudden sensorineural hearing loss group than the control group, whereas the difference was not significant for PTX-3. In the responsive and non-responsive groups, ESM-1 and PTX-3 levels were not statistically different before and after treatment.ConclusionTo our knowledge, this is the first study investigating plasma ESM-1 and PTX-3 levels in idiopathic sudden sensorineural hearing loss. Increased plasma ESM-1 levels may confirm endothelial dysfunction involvement in idiopathic sudden sensorineural hearing loss pathogenesis, which could be associated with vascular impairment.

Sign in / Sign up

Export Citation Format

Share Document